Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide
Conditions:   Primary Immune Deficiency Disorder;   Immune Deficiency Disease;   Bone Marrow Failure Interventions:   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Radiation: Low Dose Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2020 Category: Research Source Type: clinical trials

Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide
Conditions:   Primary Immune Deficiency Disorder;   Immune Deficiency Disease;   Bone Marrow Failure Interventions:   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Radiation: Low Dose Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2020 Category: Research Source Type: clinical trials

Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide
Conditions:   Primary Immune Deficiency Disorder;   Immune Deficiency Disease;   Bone Marrow Failure Interventions:   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Radiation: Low Dose Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 16, 2020 Category: Research Source Type: clinical trials

A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)
Condition:   Bone Marrow Disease Intervention:   Biological: CK0801 Sponsor:   Cellenkos, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 12, 2018 Category: Research Source Type: clinical trials

Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH
Condition:   PNH Intervention:   Sponsor:   Handok Pharmaceuticals Co., Ltd. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 9, 2018 Category: Research Source Type: clinical trials

UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep
Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Ma...
Source: ClinicalTrials.gov - March 24, 2016 Category: Research Source Type: clinical trials